Current therapy and antiviral drugs under evaluation
Despite the availability of an efficient vaccine, chronic hepatitis B virus (HBV) infection still represents a major public health concern worldwide. Viral persistence is responsible for most of the clinical complications of the disease and treatment failure. Currently, only three agents are registered for the treatment of chronic hepatitis B: interferon alpha (IFN-α), an antiviral and immunostimulatory cytokine and lamivudine and adefovir dipivoxil, two nucleoside analogues (Lai et al., 1998; Marcellin et al., 2003; Wong et al., 1993) . Many other drugs are in clinical development such as entecavir, emtricitabine, telbivudine, clevudine, elvucitabine, pegylated interferon and therapeutic vaccines, while others, such as tenofovir, have been registered for the treatment of HIV infection but also exhibit a significant anti-HBV activity. Due to the slow kinetics of viral clearance and the deficient immune response against HBV-infected cells in the majority of chronic carriers, antiviral therapy of chronic hepatitis B remains a challenge. One of the major problems with IFN-α and its pegylated forms is the relatively low response rate and the side effects associated with their administration, thus preventing their long-term use. With currently available nucleoside analogues, long-term antiviral therapy is required to control viral replication and avoid a rebound of viral replication, but this exposes the patient to the development of drug resistance.
Viral replication and the targets for antiviral therapy
HBV is a DNA virus that belongs to the hepadnavirus family and infects mainly hepatocytes, although other extrahepatic reservoirs have been described. All the viruses of this family share the same replication strategy [for more detail see (Ganem & Prince, 2004; ]. The major characteristics of the replication cycle that are relevant to antiviral therapy are the following: i) HBV replication does not induce a cytopathic effect in infected cells, which in turn is one of the factors involved in viral persistence; ii) viral covalently closed circular DNA (cccDNA) is the transcriptionally active form of viral genome and has been shown to have a long half-life in infected cells; and iii) viral genome replication occurs via a reverse transcription step that leads to the production of viral DNA genome within nucleocapsids, which are then Keywords: hepatitis B virus, hepadnavirus, viral persistence, drug resistance enveloped prior to virion release. The reverse transcriptase activity also generates viral mutants at each replication cycle. Furthermore, viral nucleocapsids may also be recycled back to the nucleus to initally amplify and then maintain a stable pool of viral cccDNA in the liver. The viral polymerase has been the main target for the development of antivirals of the nucleoside analogue family. Most of these compounds inhibit the RNA-dependent DNA polymerase activity of the viral polymerase, while other inhibitors are more specific to the DNA-dependent DNA polymerase activity. Although these agents are potent inhibitors of the viral polymerase activity, tissue culture and in vivo experiments have shown that their long-term administration does not lead to complete clearance of viral cccDNA from infected cells (Mason et al., 1998; Moraleda et al., 1997) .
Other steps of the replication cycle are potentially relevant for the development of specific inhibitors (see Table 1 ).
Cytolytic versus non-cytolytic clearance of viral infection
The understanding of the mechanisms involved in the spontaneous viral clearance are critical for the design of new regimens or novel concepts of antiviral therapy. In the transgenic mice and chimpanzee models, it was shown that a non-cytolytic TH1 response decreases viral replication and the number of cells supporting viral gene expression and replication. This antiviral effect is mediated by the in situ expression in the infected liver of cytokines such as interferon gamma (IFN-γ), interleukin 12 and tumour Inhibitor of elongation of (-) DNA Selection of drug-resistant mutants Active against adefovir-resistant strains Clevudine Inhibitor of (+) DNA synthesis Inactive against lamivudine-resistant mutants Elvucitabine
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Inhibitors of viral assembly Active against lamivudine-resistant mutants necrosis factor alpha, leading to the curing of infected cells (Cavanaugh et al., 1997; Guidotti et al., 1999; Wieland et al., 2004) . On the other hand, in other hepadnavirus infection models, that is, the duck and woodchuck models, it was shown that spontaneous and antiviral-mediated viral clearance mainly involves the lysis of infected cells and cell turnover. The latter generates non-infected cells and dilutes the remaining infected cells (Fourel et al., 1994; Guo et al., 2000; Summers et al., 2003; Summers & Mason, 2004) . It was also shown that the rapid resolution of viral infection involves the production of anti-envelope antibodies that may neutralize the circulating virions.
Whether or not the differences observed are due to the specific animal models that have been studied remains to be determined. However, based on all these data as well as clinical observations, it seems that a concerted and timely action of a cytotoxic and non-cytotoxic CD8 response, with hepatocyte turnover and production of neutralizing antibodies, is required to clear viral infection from the liver in acutely infected animals ( Figure 1 ) (Summers et al., 2003; Wieland et al., 2004) . This may have important implications in terms of antiviral therapy of chronic hepatitis B in the clinical setting for the design of improved protocols using nucleoside analogues or antiviral cytokines to achieve a sustained control of viral replication.
Inhibition of viral production by antiviral agents
Nucleoside and nucleotide analogues inhibit the viral polymerase activity of the reverse transcriptase and consequently decrease viral production from infected cells, which in turn prevents the infection of new cells. However, infected cells have a relatively long half-life especially in patients who are not able to mount a vigorous CD4 and CD8 T-cell response against infected cells. Therefore, kinetics of viral clearance follow a two-phase decay schematically, the first one reflecting the inhibition of viral production and the second one the half-life of infected cells (Lewin et al., 2001; Nowak et al., 1996; Tsiang et al., 1999) . Since the half-life of viral cccDNA within infected cells is also long and does not seem to be significantly affected by nucleoside analogues, this explains the requirement for long-term therapy of chronic HBV infection. Furthermore, it was shown that none of the currently available polymerase inhibitors can inhibit the de novo formation of viral cccDNA in a newly infected cell (Delmas et al., 2002; Kock et al., 2003; Seigneres et al., 2003) , suggesting that during antiviral therapy, residual circulating virions may still be capable of infecting new cells, thus delaying the time of clearance of infected cells.
On the other hand, it was shown that antiviral therapy with polymerase inhibitors may indirectly restore the immune response against infected cells. Several studies have shown that the vigour of the CD4 and CD8 T-cell response is enhanced when viral load decreases (Webster et al., 2004) . Other elegant studies have shown that the decrease of viral load induced by lamivudine or adefovir administration is accompanied by a restoration of CD4 response against HBV epitopes followed by a specific CD8 response, leading to a sustained control of viral replication and clinical improvement (Boni et al., 1998; Boni et al., 2001) . These results may serve in the future to help design new antiviral therapy protocols based on the combination of polymerase inhibitors and immune stimulators that may need to be administered when a substantial restoration of immune responses has been already achieved.
Can we clear intrahepatic cccDNA from a chronically infected liver?
HBV cccDNA is a unique episomal replicative intermediate proposed to be responsible for viral persistence during chronic hepatitis B (Tuttleman et al., 1986) . Indirect evidence suggests that cccDNA persists for decades even when viral replication is fully suppressed by host-mediated immunity or during short-term suppression with antivirals (Rehermann et al., 1996; Zhu et al., 2001) . Studies performed in animal models of hepadnavirus infection have provided strong evidence that this viral DNA form is a key determinant in treatment failure and one of the viral factors involved in the selection of drug-resistant virus (Le Guerhier et al., 2000; Le Guerhier et al., 2001; Mason et al., 1998; Seigneres et al., 2003; Zhou et al., 1999) . Due to technical limitations, the current understanding of cccDNA persistence has been gathered almost exclusively from animal hepadnavirus models (Guidotti et al., 1999; Guo et al., 2000; Summers et al., 2003; Wieland et al., 2004) .
Recently, a specific study was performed to gain novel insight on the persistence of cccDNA and its clearance mechanisms in chronically infected patients. Results showed that intrahepatic cccDNA is present at levels ranging over three orders of magnitude in patients in different phases of the natural history of chronic hepatitis B, including those with immunologically resolved infection. These data provide direct evidence that control of HBV infection occurs through long-term host-mediated control of viral replication rather than sterilizing immunity . During a 48-week clinical study, patients receiving adefovir dipivoxil therapy exhibited a significant decline in cccDNA levels compared with those in the placebo group . Decline in cccDNA levels was slower than that of total intrahepatic HBV DNA and serum HBV DNA, and probably contributes to the slow second phase of viral clearance previously observed during kinetic analyses of viral load decay in chronic hepatitis B patients (Tsiang et al., 1999) . Based on mathematical modelling, it would take approximately 14.5 years to completely clear intracellular cccDNA from a chronically HBV-infected human liver. Interestingly, the decrease in HBsAg titre was correlated with changes in intrahepatic cccDNA, total intrahepatic HBV DNA and serum HBV DNA. This provided further evidence that adefovir dipivoxil therapy reduces the reservoir of transcriptionally active cccDNA. Results of immunohistochemical staining studies of matched biopsies and of baseline indicators of liver damage suggest that during adefovir dipivoxil therapy, cccDNA may be cleared by non-cytolytic mechanisms rather than by cell killing and turnover. Thus, the decrease in intrahepatic cccDNA may result from the inhibition of both viral DNA synthesis and intracellular recycling of viral nucleocapsid . Clinical studies are ongoing to determine the relevance of cccDNA quantification as a clinical endpoint, as well as the use of non-invasive surrogate markers such as the quantification of circulating viral antigens to monitor antiviral therapy and tailor its duration to the virological situation of each patient.
HBV genome variability and viral drug resistance
Viral genome variability is another important viral factor involved in viral persistence that may lead to the selection of escape mutants, depending on the selective pressure. Viral genome replication requires a step of reverse transcription, which constitutively generates the production of HBV mutants, as the viral polymerase lacks a 3′, 5′ proof reading activity. During long-term therapy with nucleoside analogues that specifically inhibit the viral reverse transcriptase activity, viral polymerase mutants that are resistant to these agents can be selected. With lamivudine administration, drug-resistant mutants are selected in approximately 40% of patients after 2 years of treatment (Lai et al., 2003) . The main mutations are located in the YMDD motif in the C domain of the viral polymerase (M204V or M204I) and may be associated with compensatory mutations in the B domain (L180M or V173L) Seigneres et al., 2002) . With adefovir dipivoxil administration, the resistant mutants are selected at a slower rate (that is, 4% after 3 years of treat-Antiviral therapy of chronic hepatitis B ment). These mutations are located in the B domain (A181V/T) or in the D domain (N236T) of the reverse transcriptase (Angus et al., 2003; Villeneuve et al., 2003) .
Although the crystal structure of an enzymatically active HBV polymerase has not yet been obtained, threedimensional models of the HBV reverse transcriptase have been created based on sequence homology with the HIV reverse transcriptase (Bartholomeusz et al., 2004; Das et al., 2001; Lee & Chu, 2001 ). These models have permitted the proposal that the mechanisms involved in lamivudine and adefovir resistance differ significantly with respect to the interaction of the drugs with the putative nucleotide binding site and the catalytic site of the viral enzyme.
Recently, new insight into the biology of the drugresistant mutants has been gained with the development of new assays that allow the cloning of the viral genome from clinical isolates and the study of their phenotype (replication capacity and drug susceptibility) after transfection of eukaryotic cells in tissue culture (Allen et al., 1998; Durantel et al., 2004; Yang et al., 2004) . Very interesting results were obtained from these studies. It was shown that the lamivudine-resistant strains have a more than 100-fold reduction in lamivudine susceptibility and that the B domain mutations restore a higher replication capacity to the C domain mutants. Interestingly, differences in drug susceptibility were observed depending on the cell line used, which may indicate significant differences in drug metabolism in these cells. Phenotypic analysis of the adefovir-resistant strains showed that these mutants are less susceptible to adefovir in tissue culture but are not fully resistant, which may explain the slower rate of selection of these drug-resistant mutants. Moreover, it was shown that the lamivudine-and adefovirresistant mutants are not cross resistant in vitro and in vivo, which provides a strong argument for the evaluation of combination therapy with these drugs or other agents that do not share the same cross-resistance profile (Zoulim, 2003) . This antiviral profile may be explained by the fact that the mutations confering resistance to lamivudine or to adefovir are not located in the same polymerase domains and do not share the same mechanism confering drug resistance. The use of more rapid phenotypic assays for the monitoring of antiviral therapy may prove to be clinically relevant when more anti-HBV agents are available for the treatment of chronic hepatitis B (entecavir, emtricitabine, telbivudine, tenofovir, elvucitabine, and so on).
New concepts of antiviral therapy of chronic HBV infection
With better knowledge of the molecular biology of HBV and the availability of new tools, it appears clear that an optimal monitoring of antiviral therapy will rely on the use of more sensitive assays for the quantification of serum viral load, genotypic asssays for the early detection of drug resistant mutants and phenotypic assays to adapt antiviral therapy to the circulating strain in patients. Furthermore, the recent data regarding the cross-resistance studies made with lamivudine and adefovir resistant strains, suggest that a combination therapy with both drugs or others without cross resistance should be evaluated clinically to determine if such a strategy will delay or prevent the onset of drug resistance in patients receiving antiviral therapy. The experience with combination therapy in HIV infection strongly argues that this should be the case (Clavel & Hance, 2004) . The development of new drugs with different mechanisms of action and drug-resistance profiles will provide new opportunities to assess the long-term efficacy of combinations of nucleoside analogues in terms of prevention of drug resistance and clearance of viral cccDNA and infected cells.
So far, the combination of polymerase inhibitors and IFN-α (pegylated or not) has not proven to be more effective than either regimen alone in terms of sustained virological response. This may be due to the fact that the vigour and time of restoration of immune response during nucleoside analogue therapy may greatly vary from patient to patient and that IFN-α may have not been administered in a timely manner. Other approaches are under evaluation, such as the combination of nucleoside analogues and immunomodulatory strategies based on vaccine therapy or the administration of TH1 cytokines. Interestingly, it was shown in experimental models of HBV infection that envelope protein recombinant vaccine therapy may increase the rate of sustained immunological response in woodchucks treated with clevudine (Menne et al., 2002) and that a viral envelope expressing DNA vaccine administration may enhance the antiviral activity of adefovir, leading to an increased rate of viral clearance in the duck model (Le Guerhier et al., 2003; Rollier et al., 1999) . DNA vaccine in a transgenic mouse model also induced a specific antiviral response: CD8+ or CD4+ T lymphocytes from immunocompetent DNA-immunized animals were sufficient to control viral gene expression in the livers of the recipient transgenic mice. This effect was mediated by a cytokinedependent mechanism common to both T-cell subpopulations. This mechanism did not require cell lysis, but involved the production of IFN-γ by the activated T cells (Mancini et al., 1998) . On the other hand, it was shown that the intrahepatic delivery of IFN-γ, a TH1 cytokine, in woodchucks in whom viral load was significantly decreased by a combination of two nucleoside analogues (clevudine and emtricitabine), did not increase the rate of clearance of cccDNA and infected cells from the liver of these animals ( Jacquard et al., 2004) . However, in the woodchuck model, it was also shown by other investigators that IFN-γ does not deplete infected cells from viral replicative intermediates (Lu et al., 2002) . Further studies are therefore required to gain more insight into the immunological response against HBV-infected cells and the therapeutic consequences (Figure 1) .
Other less conventional strategies targeting other steps of the viral life cycle are also in experimental evaluation (see Table 1 ). One potential interest of these strategies is that, by targeting non-polymerase steps of viral replication, they would be able to achieve an inhibitory effect even on the replication of nucleoside analogue-resistant strains (for more detail, see the review (Zoulim, 2004) . All these developments should lead in the near future to a very exciting time for the evaluation and development of improved antiviral strategies for chronic HBV infections.
